Payment overview · 2025
General Payments
$1,711.95
112 reported records · 29 companies
Healthcare provider profile · identity verified
Michael A Hassman, DO
Allopathic & Osteopathic Physicians|Family Medicine|Adult Medicine · BERLIN, NJ · NPI 1922002765
Verified facts
What the public records show
CMS Open Payments records show Michael A Hassman, DO received $1,711.95 in general payments during 2025 across 112 reported records.
Madrigal Pharmaceuticals accounted for 14.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 46 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $254.48 | 14.9% | 9 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $188.28 | 11.0% | 15 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $138.52 | 8.1% | 14 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $105.91 | 6.2% | 7 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $88.56 | 5.2% | 5 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $87.64 | 5.1% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $84.18 | 4.9% | 5 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $73.66 | 4.3% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $72.30 | 4.2% | 8 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $68.68 | 4.0% | 4 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $68.11 | 4.0% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $66.13 | 3.9% | 3 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $52.69 | 3.1% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $46.21 | 2.7% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $43.47 | 2.5% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $36.46 | 2.1% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $34.15 | 2.0% | 2 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $22.28 | 1.3% | 1 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $20.45 | 1.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.75 | 1.1% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $19.24 | 1.1% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $19.17 | 1.1% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $19.08 | 1.1% | 1 | 2025 |
| ModernaTX, Inc. | Unresolved — no canonical attribution shown | $17.00 | 1.0% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.70 | 0.9% | 1 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $14.00 | 0.8% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $13.76 | 0.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $13.57 | 0.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $8.52 | 0.5% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,711.95 | 112 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $254.48 | 9 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $142.34 | 8 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $109.92 | 9 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $109.92 | 9 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $105.91 | 7 | 2025 |
Source payment records
|
|||||
| VIVITROL Normalized: vivitrol |
Drug | Alkermes, Inc. | $88.56 | 5 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $87.64 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $82.71 | 9 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $82.71 | 9 | 2025 |
Source payment records
|
|||||
| OMVOH Normalized: omvoh |
Drug | Lilly USA, LLC | $77.38 | 5 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $68.11 | 8 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $68.11 | 8 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $55.81 | 5 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $52.69 | 3 | 2025 |
Source payment records
|
|||||
| SIMPONI Normalized: simponi |
Biological | Janssen Biotech, Inc. | $52.52 | 3 | 2025 |
Source payment records
|
|||||
| SIMPONI ARIA Normalized: simponi aria |
Biological | Janssen Biotech, Inc. | $52.52 | 3 | 2025 |
Source payment records
|
|||||
| STELARA Normalized: stelara |
Biological | Janssen Biotech, Inc. | $52.52 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $49.73 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $46.21 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $43.47 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $36.46 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $36.35 | 4 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $35.95 | 4 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $35.95 | 4 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $35.95 | 4 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $34.15 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $33.41 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $33.41 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $32.69 | 2 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $22.28 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $21.96 | 3 | 2025 |
Source payment records
|
|||||
| Hillrom - Carnation Ambulatory Monitor Normalized: hillrom carnation ambulatory monitor |
Device | Baxter Healthcare | $20.45 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.75 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $19.24 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $19.17 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $18.65 | 3 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $18.08 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $17.70 | 1 | 2025 |
Source payment records
|
|||||
| mResvia Normalized: mresvia |
Drug | ModernaTX, Inc. | $17.00 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.40 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.86 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $15.70 | 1 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $14.00 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $13.57 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $9.07 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $8.52 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 282 | 45 |
| Alprazolam | Alprazolam | 200 | 41 |
| Atorvastatin Calcium | Atorvastatin Calcium | 200 | 62 |
| Amlodipine Besylate | Amlodipine Besylate | 184 | 47 |
| Levothyroxine Sodium | Levothyroxine Sodium | 145 | 35 |
| Tramadol Hcl | Tramadol Hcl | 116 | 29 |
| Lisinopril | Lisinopril | 113 | 34 |
| Zolpidem Tartrate | Zolpidem Tartrate | 105 | 22 |
| Ibuprofen | Ibuprofen | 104 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 102 | 25 |
| Topiramate | Topiramate | 92 | 19 |
| Famotidine | Famotidine | 90 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 87 | 25 |
| Metformin Hcl | Metformin Hcl | 83 | 29 |
| Omeprazole | Omeprazole | 83 | 24 |
| Gabapentin | Gabapentin | 82 | 21 |
| Metoprolol Succinate | Metoprolol Succinate | 82 | 26 |
| Celecoxib | Celecoxib | 80 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 73 | 19 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 73 | 21 |
| Clonazepam | Clonazepam | 72 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 71 | 21 |
| Sertraline Hcl | Sertraline Hcl | 70 | 15 |
| Oxycodone Hcl | Oxycodone Hcl | 65 | suppressed |
| Losartan Potassium | Losartan Potassium | 64 | 21 |
| Furosemide | Furosemide | 63 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 63 | 16 |
| Temazepam | Temazepam | 54 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 50 | 18 |
| Meloxicam | Meloxicam | 47 | 17 |
| Carvedilol | Carvedilol | 44 | 15 |
| Montelukast Sodium | Montelukast Sodium | 43 | 14 |
| Diazepam | Diazepam | 42 | suppressed |
| Simvastatin | Simvastatin | 42 | 16 |
| Buspirone Hcl | Buspirone Hcl | 40 | 14 |
| Pregabalin | Pregabalin | 40 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 39 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 38 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 38 | suppressed |
| Mirtazapine | Mirtazapine | 37 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | suppressed |
| Eliquis | Apixaban | 35 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 35 | suppressed |
| Glipizide Er | Glipizide | 33 | suppressed |
| Glimepiride | Glimepiride | 32 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 32 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 31 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 30 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 30 | suppressed |
| Memantine Hcl | Memantine Hcl | 29 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 29 | suppressed |
| Potassium Chloride | Potassium Chloride | 29 | suppressed |
| Prednisone | Prednisone | 29 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 27 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 26 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Baclofen | Baclofen | 25 | suppressed |
| Naproxen | Naproxen | 24 | 11 |
| Amoxicillin | Amoxicillin | 23 | 23 |
| Jardiance | Empagliflozin | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 17 |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 15 |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 19 | suppressed |
| Acarbose | Acarbose | 18 | suppressed |
| Carisoprodol | Carisoprodol | 18 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 18 | suppressed |
| Oxycontin | Oxycodone Hcl | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | 13 |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 13 | suppressed |
| Allopurinol | Allopurinol | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Ozempic | Semaglutide | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Azithromycin | Azithromycin | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Endocet | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Repaglinide | Repaglinide | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,711.95 · 112 records | Madrigal Pharmaceuticals | ABRYSVO, AIRSUPRA, APTIMA, Auvelity, BREZTRI, BRIXADI, CAPVAXIVE, COMIRNATY, CREON, Cologuard Collection Kit, ELIQUIS, ENFLONSIA, EVENITY, FANAPT, GARDASIL 9, Hillrom - Carnation Ambulatory Monitor, Kerendia, Korlym, MOUNJARO, NURTEC ODT, OMVOH, OTEZLA, Omnipod, Ozempic, PREVNAR 20, PROLIA, QULIPTA, REPATHA, REXULTI, REZDIFFRA, Rybelsus, SHINGRIX, SIMPONI, SIMPONI ARIA, SPRAVATO, STELARA, TREMFYA, UBRELVY, VIVITROL, VOQUEZNA, VRAYLAR, XIFAXAN, ZAVZPRET, ZEPBOUND, ZORYVE, mResvia | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error